Ameriprise
RLAY icon

Ameriprise’s Relay Therapeutics RLAY Stock Holding History

Ameriprise’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.55M Buy
+356,924
New +$3.19M ﹤0.01% 2657
2025
Q3 		– Sell
-410,896
Closed -$1.42M – 4169
2025
Q2 		$1.42M Buy
410,896
+38,543
+10% +$115K ﹤0.01% 3115
2025
Q1 		$976K Buy
372,353
+66,912
+22% +$262K ﹤0.01% 3219
2024
Q4 		$1.26M Buy
305,441
+28,989
+10% +$158K ﹤0.01% 3136
2024
Q3 		$1.96M Buy
276,452
+56,727
+26% +$424K ﹤0.01% 2929
2024
Q2 		$1.43M Sell
219,725
-230,447
-51% -$1.57M ﹤0.01% 3006
2024
Q1 		$3.74M Sell
450,172
-9,371
-2% -$91.4K ﹤0.01% 2544
2023
Q4 		$5.06M Buy
459,543
+364,327
+383% +$3.07M ﹤0.01% 2341
2023
Q3 		$801K Buy
95,216
+6,958
+8% +$74.8K ﹤0.01% 3236
2023
Q2 		$1.11M Sell
88,258
-16,139
-15% -$201K ﹤0.01% 3125
2023
Q1 		$1.72M Buy
104,397
+19,920
+24% +$357K ﹤0.01% 2910
2022
Q4 		$1.26M Sell
84,477
-806
-0.9% -$15.4K ﹤0.01% 3022
2022
Q3 		$1.91M Buy
85,283
+227
+0.3% +$4.98K ﹤0.01% 2806
2022
Q2 		$1.43M Buy
85,056
+12,002
+16% +$257K ﹤0.01% 2963
2022
Q1 		$2.19M Buy
73,054
+8,156
+13% +$198K ﹤0.01% 2871
2021
Q4 		$1.99M Buy
64,898
+21,723
+50% +$686K ﹤0.01% 2962
2021
Q3 		$1.36M Buy
43,175
+3,584
+9% +$121K ﹤0.01% 3028
2021
Q2 		$1.45M Buy
39,591
+3,205
+9% +$106K ﹤0.01% 3055
2021
Q1 		$1.26M Sell
36,386
-7,927
-18% -$344K ﹤0.01% 3052
2020
Q4 		$1.84M Sell
44,313
-1,532
-3% -$69.3K ﹤0.01% 2835
2020
Q3 		$1.95M Buy
+45,845
New +$1.75M ﹤0.01% 2683

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Ameriprise's RLAY Position: Q1 2026 in Review

Ameriprise opened a new position in Relay Therapeutics (RLAY) in Q1 2026: 356,924 shares worth $3.55M. The stake represents ﹤0.01% of the portfolio and ranks #2657 among its holdings. This is a return to the name: Ameriprise previously reported a position in RLAY as recently as Q2 2025.

Ameriprise first reported a position in RLAY in Q3 2020 and has held it in 21 quarters since. The position peaked at $5.06M in Q4 2023. 243 funds tracked by Wall St. Rank hold RLAY as of Q1 2026.

  • Ameriprise held 356,924 shares of Relay Therapeutics worth $3.55M as of Q1 2026.
  • Relay Therapeutics was a new Ameriprise position in Q1 2026.
  • Relay Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #2657 holding.
  • Ameriprise first reported a position in Relay Therapeutics in Q3 2020 and has held it in 21 quarters since.
  • Ameriprise's Relay Therapeutics position peaked at $5.06M in Q4 2023.
  • 243 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.